Nu-Med Plus (NUMD) Cash from Operations Growth (5y) (2017 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (5y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.26 Bn | 175.96 Bn | 6.27 Bn |
| 2 | Stryker | 128.79 Bn | 125.92 Bn | 3.81 Bn |
| 3 | Medtronic | 108.56 Bn | 99.34 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.31 Bn | 66.86 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.27 Bn | 43.60 Bn | 1.29 Bn |
| 6 | Dexcom | 28.42 Bn | 27.31 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.12 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.40 Bn | 2.07 Bn |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.23% |
| Sep 30, 2025 | 35.34% |
| Dec 31, 2024 | 57.80% |
| Jun 30, 2024 | 54.64% |
| Mar 31, 2024 | 71.67% |
| Dec 31, 2023 | 50.45% |
| Sep 30, 2023 | 33.30% |
| Jun 30, 2023 | 25.35% |
| Mar 31, 2023 | 24.42% |
| Dec 31, 2022 | 29.39% |
| Sep 30, 2022 | 14.93% |
| Jun 30, 2022 | 50.98% |
| Mar 31, 2022 | 30.32% |
| Dec 31, 2021 | 13.33% |
| Sep 30, 2021 | -1.03% |
| Jun 30, 2021 | -5.93% |
| Mar 31, 2021 | -9.53% |
| Dec 31, 2020 | -8.44% |
| Sep 30, 2020 | -20.78% |
| Jun 30, 2020 | -22.78% |